Struggling Vermillion to Expand Business Strategy Beyond Proteomics-based Testing | GenomeWeb

NEW YORK (Genomeweb News) – Having struggled unsuccessfully for several years (and through several management teams) to drive adoption of its OVA1 ovarian cancer test, Vermillion said this week that it is shifting to a new strategy in which it will seek to broaden its business beyond proteomics-based diagnostics to encompass a variety of testing tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.